Business Overview: AdaptHealth Corp. (Nasdaq: AHCO)

---

Executive Summary

AdaptHealth Corp. is one of the largest providers of home medical equipment (HME) and services in the United States, delivering durable medical equipment and related supplies directly to patients in their homes. Headquartered in Plymouth Meeting, Pennsylvania, AdaptHealth's core categories include sleep therapy (CPAP/BiPAP equipment and supplies), diabetes management supplies (continuous glucose monitors, insulin pumps, testing supplies), home respiratory therapy (oxygen concentrators, ventilators), and wound care/orthotics.

AdaptHealth built its national scale primarily through an aggressive multi-year roll-up acquisition strategy, consolidating dozens of regional home medical equipment providers into a single national platform with centralized purchasing, billing, and payer-contracting capabilities.

---

1. Core Business Model & How They Work

AdaptHealth's model centers on recurring resupply revenue layered on top of initial equipment setup:

[ Physician Prescribes DME (CPAP, oxygen, CGM, etc.) ] ➡️ [ AdaptHealth Delivers & Sets Up Equipment ] ➡️ [ Bills Medicare/Medicaid/Commercial Payer ] ➡️ [ Recurring Resupply of Consumables ] ➡️ [ Ongoing Patient Relationship ]

Key Operational Drivers

1. Recurring Resupply Revenue: Many of AdaptHealth's core categories (CPAP masks/filters, diabetes testing supplies, incontinence products) require regular resupply, generating a recurring revenue stream once a patient relationship is established.
2. Payer Mix and Reimbursement: A large share of revenue flows through Medicare and Medicaid reimbursement, making the company sensitive to CMS rate-setting, including competitive bidding programs for DME categories.
3. Scale-Driven Purchasing and Contracting: National scale gives AdaptHealth negotiating leverage with equipment manufacturers and payers relative to smaller regional competitors.
4. M&A Integration: Historical growth relied heavily on acquiring and integrating smaller regional HME providers; more recent years have focused on organic growth and operational integration of the acquired platform.

---

2. Business Segments / Product Categories

• Sleep Therapy: CPAP and BiPAP devices and consumable supplies for obstructive sleep apnea patients — one of the largest and most recurring-revenue categories.
• Diabetes Management: Continuous glucose monitors, insulin pumps, and related testing supplies, a growing category tied to rising diabetes prevalence and CGM adoption.
• Respiratory: Home oxygen concentrators, ventilators, and nebulizers for chronic respiratory conditions such as COPD.
• Wound Care, Orthotics & Other HME: Additional home medical equipment and supply categories serving post-acute and chronic care patients.

---

3. Competitive Landscape

                  National Scale HME Providers
                              │
       AdaptHealth (AHCO) ●────────────────── ● Rotech Healthcare
                              │
        Lincare (Linde subsidiary) ●
                              │
              Apria (Owens & Minor subsidiary) ●
                              │
                 Regional/Independent HME Providers

Key Competitors

• Lincare Holdings (a Linde plc subsidiary): One of the largest home respiratory and HME providers, with significant scale in oxygen therapy.
• Apria (acquired by Owens & Minor): A major national competitor across respiratory, sleep, and other home healthcare equipment categories.
• Rotech Healthcare: A national HME provider with a strong footprint in respiratory therapy and durable medical equipment.
• Numerous regional and local DME providers: The industry remains fragmented at the local level, giving national players continued opportunity for consolidation.

Dynamics

Competitive intensity centers on payer contracting, referral relationships with physicians and hospital discharge planners, and the ability to service patients reliably (equipment delivery, insurance billing complexity, resupply logistics) — areas where national scale provides real advantages, but where local relationships with referring physicians still matter significantly.

---

4. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• National scale and payer contracting leverage: Size gives AdaptHealth negotiating leverage with both equipment suppliers and commercial payers that smaller regional competitors lack.
• Recurring resupply relationships: Once a patient begins receiving supplies (CPAP masks, CGM sensors, diabetic testing strips), the recurring nature of resupply orders creates a sticky, repeat-revenue relationship.
• Broad service footprint: A national delivery and logistics network supports serving large multi-state payers and referral networks that a regional provider cannot service alone.

Strategic Risks & Vulnerabilities

1. Reimbursement rate risk: CMS competitive bidding programs and periodic reimbursement rate reductions for DME categories directly pressure revenue and margins.
   • Mitigation: Diversification across multiple HME categories and continued shift toward higher-growth categories like diabetes management.
2. Integration and leverage from historical M&A: Years of acquisitive growth left the company with integration complexity and balance sheet leverage that require ongoing operational discipline to manage.
3. Competitive intensity from both national and regional players: Referral relationships can shift to competitors, and national payers periodically re-bid network contracts.
4. Working capital and billing complexity: Managing insurance billing and collections across Medicare, Medicaid, and numerous commercial payers is operationally complex and can create receivables and cash flow variability.

---

5. Financial Overview & Performance Matrix

---

6. Summary Conclusion

AdaptHealth has built one of the largest national platforms in home medical equipment by consolidating a historically fragmented, locally-served industry, creating scale advantages in purchasing, payer contracting, and multi-state service capability that smaller competitors cannot easily match.

The central long-term question is whether the company can convert its scale into durable organic growth and margin expansion — particularly by growing recurring resupply relationships in categories like diabetes management — while successfully managing reimbursement rate risk and the balance sheet leverage built up during its acquisitive growth phase.